Evaluation of (177)Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors

BACKGROUND: (177)Lu peptide receptor radionuclide therapy (PRRT) is a recently approved therapy in Spain that has been demonstrated to be a well-tolerated therapy for positive somatostatin receptor advanced gastroenteropancreatic neuroendocrine tumors. AIM: To determine the impact of PRRT on quality...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou Jokh Casas, Estephany, Pubul Núñez, Virginia, Anido-Herranz, Urbano, del Carmen Mallón Araujo, María, del Carmen Pombo Pasín, Maria, Garrido Pumar, Miguel, Cabezas Agrícola, José Manuel, Cameselle-Teijeiro, José Manuel, Hilal, Ashraf, Ruibal Morell, Álvaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152518/
https://www.ncbi.nlm.nih.gov/pubmed/32308351
http://dx.doi.org/10.3748/wjg.v26.i13.1513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152518/
https://www.ncbi.nlm.nih.gov/pubmed/32308351
http://dx.doi.org/10.3748/wjg.v26.i13.1513

Ejemplares similares